Start of therapy of type 2 diabetes mellitus with a fixed combination. Metformin with vildagliptin or glibenclamide, is there any difference?


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. The widespread prevalence of type 2 diabetes mellitus (DM2), the associated high mortality and disability of patients are the reason for the constant active search for effective approaches to hypoglycemic therapy. The right choice of drugs for the initial DM2 treatment is especially relevant, which can lay the foundation for achieving long-term goals of glycemic control, thereby preventing the development of serious complications. In our work, we studied one of the approaches to the initial DM2 treatment, namely the use of a fixed combination of vildagliptin+meformin at a dose of50/1000 mg twice a day compared with the more conventional treatment option: a fixed combination of glibenclamide and metformin at a dose of2.5/500 mg twice a day. Objective. Evaluation of the dynamics of glycemic control indicators, body mass index (BMI) and the time-to-3rd hypoglicemic drug for patients with T2DM who received one of the listed options for a fixed combination at the start of therapy. Methods. Study sample was formed from the database of the Moscow segment of the Federal Diabetes Register, which was used as a data source. Results. Moreover, by the end of the observation, a statistically significant lower glycated hemoglobin (НЬАіс) level and BMI was observed in patients receiving vildagliptin+metformincompared to patients receiving glibenclamide+metformin (p<0.05). After 8 years of follow-up, 62.5% of patients from the vildagliptin+metformin group and 44.3% of patients from the glibenclamide+metformin group had an HbAlc level of <7.0% (p<0.05). Conclusion. The observation confirmed the possibility of maintaining long-term stable glycemic control without gaining body weight in DM2 patients who received a combination of vildagliptin+metformin.

Full Text

Restricted Access

About the authors

Nikolai A. Demidov

Hospital in Moskovsky town of the Moscow Healthcare Department

Email: nicolay13@mail.ru
PhD, Endocrinologist

O. M Koteshkova

Endocrinological Dispensary of the Moscow Healthcare Department

M. A Balberova

Hospital “Kuznechiki" of the Moscow Healthcare Department

M. B Antsiferov

Endocrinological Dispensary of the Moscow Healthcare Department

References

  1. International Diabetes Federation. Diabetes Atlas, 8th ed. 2017
  2. Дедов И.И., Шестакова М.В., Викулова О.К. Эпидемиология сахарного диабета в Российской Федерации: клинико-статистический анализ по данным Федерального регистра сахарного диабет. Сахарный диабет. 2017;20(1):13 41
  3. Дедов И.И., Шестакова М.В., Галстян ГР Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016;19(2):104 12
  4. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова (8-й выпуск). Сахарный диабет. 2017;20:(Suppl. 1):1-112
  5. Госкомстат России. Здравоохранение в России 2017 г. М., 2017. [Goskomstat of Russia. Healthcare in Russia 2017. Moscow, 2017
  6. Анциферов М.Б., Дорофеева Л.Г Вилдаглиптин -новый препарат из класса ингибиторов дипептидилпептидазы-4 для лечения сахарного диабета 2 типа. Фарматека. 2009;3:12-6
  7. Анциферов М.Б. Инновационный комбинированный препарат Галвус Мет (вилдаглиптин+метформин) в лечении сахарного диабета 2 типа. Фарматека. 2009;17:30 5
  8. Van Gaal L., Hermans M.P., Daci E., et al. Effectiveness and tolerability of vildagliptin and the single pill combination of vildagliptin and metformin in «real-world» management of type2 diabetes mellitus: the G-FORCE Study. Diabetes Ther. 2019;10:965-79. doi: 10.1007/s13300-019-0601-y
  9. Hermans M., van Gaal L., Rezette I., et al. Patient engagement impacts glycemic management with vildagliptin and vildagliptin/metformin (single pill) regimens in type 2 diabetes mellitus (the GLORIOUS study). Prim. Care Diab. 2016;10(6):425-33. doi: 10.1016/j.pcd.2016.05.008.
  10. Li-Nong Ji, Chang-Yu Pan, Ju-Ming Lu, et al. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin up-titration in Chinese patients with type 2 diabetes mellitus: study design and rationale of the vision study Cardiovasc Diabetol. 2013;12:118. doi: 10.1186/1475-2840-12-118.
  11. Ahren B., Mathieu C., Bader G., et al. Efficacy of Vildagliptin versus sulfonylureas as add-on to Metformin: comparison of results from randomized controlled trials and observational studies. Diabetol. 2014;(57):1304-307. doi: 10.1007/s00125-014-3222-z.
  12. Mathieu C., Barnett A.H., Brath H., et al. Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE). Int J. Clin Pract. 2013;(67):947-56. doi: 10.1111/ijcp.12252.
  13. Strain D.W., Pald nius PM. Dipeptidyl Peptidase-4 Inhibitor Development and Postauthorisation Programme for Vildagliptin -Clinical Evidence for Optimized Management of Chronic Diseases beyond Type 2 Diabetes. Eur Endocrinol. 2017;13(2):62-7. Doi: 10.17925/ EE.2017.13.02.62.
  14. Rosales R., Abou Jaoude E., Al-Arouj M., et al. Clinical effectiveness and safety of vildagliptin in >19 000 patients with type 2 diabetes: the GUARD study. Diab Obes Metab. 2015;17(6):603-7. Doi: https://doi.org/10.1111/dom.12436.
  15. Ferrannini E., Fonseca V., Zinman B., et al. Fifty-two week efficacy and safety of Vildagliptin vs. Glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin therapy. Diab Obes Metab. 2009;11:157-66. doi: 10.1111/j.1463-1326.2008.00994.x.
  16. Schwartz S.S., Epstein S., Corkey E.B., et al. The Time Is Right for a New Classification System for Diabetes: Rationale and implications of the b-Cell-Centric Classification Schema. Diab Care 2016;39:179-86. doi: 10.2337/dc15-1585.
  17. Wu Y.J., Guo X., Li C.J., et al. Dipeptidyl peptidase-4 inhibitor, vildagliptin, inhibits pancreatic beta cell apoptosis in association with its effects suppressing endoplasmic reticulum stress in db/ db mice. Metabolism. 2015;64(2):226-35. doi: 10.1016/j.metabol.2014.08.006.
  18. Matthews D.R., Paldanius PM., Proot P., et al. Glycemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 dibetes (VERIFY): a 5 year, multicentre, randomised double-blind trial. Lancet. 2019;394(10208):1519-29. Doi: https://doi.org/10.1016/S0140-6736(19) 32131-2.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Bionika Media